James S. Scott

James S. Scott

Auto-generated profile, based on publicly available information

James S. Scott

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BJBenjamin Jeffries
Benjamin Jeffries
ZWZhong Wang
Zhong Wang
HFHannah R. Felstead
Hannah R. Felstead
JQJean-Yves Le Questel
Jean-Yves Le Questel
JSJames S. Scott
James S. Scott
BLBruno Linclau
Bruno Linclau

9 November 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
BJBenjamin Jeffries
Benjamin Jeffries
ZWZhong Wang
Zhong Wang
JGJerome GRATON
Jerome GRATON
SHSimon D. Holland
Simon D. Holland
TBThomasin Brind
Thomasin Brind
BLBruno Linclau
Bruno Linclau
Fluorination is commonly employed to optimize bioactivity and pharmaco-kinetic properties of drug candidates. Aliphatic fluorination often reduces the lipophilicity (log P), but polyfluoroalkylation typically increases lipophilicity. Hence, identification of polyfluorinated motifs that nonetheless lead to similar or even reduced lipophilicities is of interest to expand the arsenal of medicinal chemistry tools in tackling properties such as compound metabolic stability or off-target selectivity. We show that changing a CF3-group of a perfluoroalkyl chain to a methyl group leads to a drastic reduction in lipophilicity. We also show that changing a C–F bond of a trifluoromethyl group, including when incorporated as part of a perfluoroalkyl group, to a C–Me group, leads to a reduction in log P, despite the resulting chain elongation. The observed lipophilicity trends were identified in fluorinated alkanol models and reproduced when incorporated in analogues of a drug candidate, and the metabolic stability of these motifs was demonstrated.

10 September 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JSJames S. Scott
James S. Scott
TMThomas A. Moss
Thomas A. Moss
ABAmber Balazs
Amber Balazs
BBBernard Barlaam
Bernard Barlaam
JBJason Breed
Jason Breed
WYWenzhan Yang
Wenzhan Yang

6 September 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SDSébastien L. Degorce
Sébastien L. Degorce
MBMichael S. Bodnarchuk
Michael S. Bodnarchuk
ICIain A. Cumming
Iain A. Cumming
JSJames S. Scott
James S. Scott

13 December 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JSJames S. Scott
James S. Scott
FGFrederick W. Goldberg
Frederick W. Goldberg
ATAndrew V. Turnbull
Andrew V. Turnbull

19 September 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
MLMandy Lawson
Mandy Lawson
NCNatalie Cureton
Natalie Cureton
SRSusana Ros
Susana Ros
ACAzadeh Cheraghchi-Bashi
Azadeh Cheraghchi-Bashi
JUJelena Urosevic
Jelena Urosevic
LCLarissa S. Carnevalli
Larissa S. Carnevalli
Oral selective estrogen receptor degraders (SERD) could become the backbone of endocrine therapy (ET) for estrogen receptor–positive (ER+) breast cancer, as they achieve greater inhibition of ER-driven cancers than current ETs and overcome key resistance mechanisms. In this study, we evaluated the preclinical pharmacology and efficacy of the next-generation oral SERD camizestrant (AZD9833) and assessed ER–co-targeting strategies by combining camizestrant with CDK4/6 inhibitors (CDK4/6i) and PI3K/AKT/mTOR-targeted therapy in models of progression on CDK4/6i and/or ET. Camizestrant demonstrated robust and selective ER degradation, modulated ER-regulated gene expression, and induced complete ER antagonism and significant antiproliferation activity in ESR1 wild-type (ESR1wt) and mutant (ESR1m) breast cancer cell lines and patient-derived xenograft (PDX) models. Camizestrant also delivered strong antitumor activity in fulvestrant-resistant ESR1wt and ESR1m PDX models. Evaluation of camizestrant in combination with CDK4/6i (palbociclib or abemaciclib) in CDK4/6-naive and -resistant models, as well as in combination with PI3Kαi (alpelisib), mTORi (everolimus), or AKTi (capivasertib), indicated that camizestrant was active with CDK4/6i or PI3K/AKT/mTORi and that antitumor activity was further increased by the triple combination. The response was observed independently of PI3K pathway mutation status. Overall, camizestrant shows strong and broad antitumor activity in ER+ breast cancer as a monotherapy and when combined with CDK4/6i and PI3K/AKT/mTORi. Significance: Camizestrant, a next-generation oral SERD, shows promise in preclinical models of ER+ breast cancer alone and in combination with CDK4/6 and PI3K/AKT/mTOR inhibitors to address endocrine resistance, a current barrier to treatment.